Education
About Us
Working with TipRanks
Follow Us
Roche Holding Ltd (CH:RO)
:RO
Earnings Data
Report Date
Jul 23, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
10.76Last Year’s EPS
11.08Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and pipeline story: solid top‑line growth (7%), robust core operating profit expansion (+13%), multiple high‑impact regulatory approvals and a record number of NMEs advancing to Phase III. Management emphasized disciplined capital allocation, sizeable U.S. investment commitments and a busy 2026 newsflow. Key near‑term headwinds — chiefly the China diagnostics pricing reforms, higher taxes, working capital drag on cash flow, currency translation effects, LOE pressures and some safety/regulatory scrutiny around the BTK class — were acknowledged and framed as manageable. On balance the positives (growth, margin expansion, major pipeline wins and strategic launches) outweigh the negatives, while management provided a constructive 2026 outlook (mid‑single‑digit sales, high single‑digit core EPS).Company Guidance
Group Sales Growth
Group sales grew 7% in 2025 (constant exchange rates). Pharma sales grew 9% to CHF 47.7 billion; Diagnostics reported +2% overall but +7% excluding China healthcare pricing reforms.
Strong Operating Performance
Core operating profit increased 13% year‑over‑year, delivering a core operating margin expansion of +1.9 percentage points. Pharma core operating profit margin reached ~49.2%.
Core EPS and IFRS Net Income Progress
Core EPS rose ~11% for the year; IFRS net income increased 58% (noting a large prior‑year impairment base; adjusted operational comparison ~+20%).
Pipeline and Regulatory Momentum
Substantial Q4/Q4‑to‑date pipeline progress with multiple regulatory approvals and filings: EU approval for Gazyva in lupus nephritis; U.S. and EU approval of Lunsumio subcutaneous for third‑line+ follicular lymphoma; U.S. filing for giredestrant in post‑CDKi ER+/HER2‑ metastatic breast cancer.
Multiple Positive Phase III/II Readouts
Numerous successful trials including two positive Phase III fenebrutinib studies (FENtrepid in PPMS and FENhance in RMS), positive lidERA (giredestrant) adjuvant result with IDFS hazard ratio 0.70, positive Enspryng and vamikibart data, PiaSky aHUS result, additional positive Phase IIIs for Gazyva (INS and SLE) and a positive Phase II for CT‑388 in obesity.
Record Advancement of NMEs
A record 10 new molecular entities (NMEs) moved into Phase III — the largest cohort in Roche history, improving the risk‑adjusted pipeline value and future revenue potential.
Diagnostics Innovation & New Product Launches
Regulatory approvals and launches in Diagnostics included the Elecsys dengue antigen test, cobas BV/CV assay and automated clinical mass spectrometry (cobas Mass Spec 601). AXELIOS Sequencing Solution launched, positioned as a high‑throughput NGS offering (potential >CHF 1bn opportunities per product).
On‑market Brand Strength
Strong growth from key brands: Phesgo (+48%), Vabysmo (global growth; U.S. uptake improving), Xolair (+32%, >100,000 food allergy patients treated since launch), Ocrevus (9% growth and accelerating subcutaneous uptake), Polivy (U.S. patient share 36% in 1L DLBCL), Evrysdi (>21,000 patients on treatment). Hematology grew ~15% (CHF 8.6bn).
Financial Discipline and Capital Allocation
Company met/upgraded guidance during the year (ended at the top end of guidance), continued dividend increases in CHF, reduced net debt by CHF 1.1 billion year‑end, and committed to invest USD 50 billion in the U.S. over 5 years (R&D and PP&E).
Clear 2026 Guidance
Management guided 2026 to mid‑single‑digit group sales growth and high single‑digit core EPS growth, while expecting continued dividend increases and margin stabilization/expansion.
CH:RO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CH:RO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jan 29, 2026 | CHF346.40 | CHF352.60 | +1.79% |
Jul 24, 2025 | CHF277.00 | CHF280.40 | +1.23% |
Jan 30, 2025 | CHF290.35 | CHF294.81 | +1.54% |
Jul 25, 2024 | CHF287.44 | CHF295.78 | +2.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Roche Holding Ltd (CH:RO) report earnings?
Roche Holding Ltd (CH:RO) is schdueled to report earning on Jul 23, 2026, Before Open (Confirmed).
What is Roche Holding Ltd (CH:RO) earnings time?
Roche Holding Ltd (CH:RO) earnings time is at Jul 23, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Roche Holding Ltd stock?
The P/E ratio of Roche Holding Ltd is N/A.
What is CH:RO EPS forecast?
CH:RO EPS forecast for the fiscal quarter 2026 (Q2) is 10.76.